Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 1s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

The future of precision medicine in personalized cancer treatment

Naina Bhoyar[1], Himanshu Nirmal Chandu[2]

[1]Assistant Professor, Department of Pharmacy, Kalinga University, Raipur, India.
[2]Research Scholar, Department of Pharmacy, Kalinga University, Raipur, India.

Cite this paper as: Naina Bhoyar, Himanshu Nirmal Chandu, (2025) The future of precision medicine in personalized cancer treatment. *Journal of Neonatal Surgery*, 14 (1s), 373-377.

ABSTRACT

The field of cancer treatment has witnessed significant advancements with the emergence of precision medicine, which tailors treatment based on individual genetic, environmental, and lifestyle factors. This research explores the future of precision medicine in the context of personalized cancer treatment, focusing on the application of advanced technologies such as genomic sequencing, biomarker discovery, and targeted therapies. The integration of artificial intelligence (AI) and machine learning (ML) in precision oncology is revolutionizing the way we diagnose, predict, and treat cancer. By identifying specific genetic mutations and molecular characteristics unique to each patient, personalized cancer treatments can improve efficacy, reduce side effects, and increase survival rates. This paper delves into the challenges and potential of precision medicine in oncology, highlighting future directions and the role of interdisciplinary collaboration in advancing personalized cancer treatment.

Keywords: *Precision medicine, personalized cancer treatment, genomic sequencing, targeted therapies, artificial intelligence (ai), biomarkers.*

1. INTRODUCTION

Cancer remains one of the leading causes of mortality worldwide, despite decades of research and therapeutic developments. Traditional cancer treatments, including chemotherapy, radiation, and surgery, are often generalized approaches that can be ineffective due to the heterogeneity of cancer at the molecular level. Precision medicine is revolutionizing cancer care by tailoring therapies to the individual genetic and molecular profile of each patient, allowing for more accurate, effective, and personalized treatment strategies. This approach incorporates a deep understanding of the genetic mutations, biomarkers, and tumor microenvironment specific to each patient's cancer type.

Advances in genomic sequencing and biomarker discovery have paved the way for targeted therapies, which are designed to specifically attack cancer cells without harming healthy tissues. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) tools in oncology is enhancing the accuracy of diagnoses, predicting patient outcomes, and identifying novel therapeutic targets. Despite these advances, challenges such as high costs, data complexity, and the need for interdisciplinary collaboration remain barriers to the widespread adoption of precision medicine in cancer treatment.

This paper aims to explore the future of precision medicine in personalized cancer treatment, focusing on the key technological advancements, the integration of AI, and the potential for improving clinical outcomes through individualized therapies.

2. LITERATURE SURVEY

Next-generation sequencing (NGS) has become a cornerstone in the development of precision medicine. According to Mardis (2008), the sequencing of tumor genomes allows for the identification of genetic mutations that drive cancer progression. This information is crucial for selecting targeted therapies that inhibit specific cancer pathways. Studies like those by Vogelstein et al. (2013) have shown that genomic data can identify actionable mutations, leading to the development of drugs such as HER2 inhibitors for breast cancer and EGFR inhibitors for lung cancer.

Biomarkers are vital in the diagnosis and prognosis of cancer. Circulating tumor DNA (ctDNA) and tumor-specific mutations have shown promise in non-invasive cancer detection and monitoring treatment efficacy. Research by Diaz et al. (2012) demonstrated that ctDNA could be used to track the molecular evolution of tumors, allowing for more accurate monitoring of cancer recurrence and treatment response.

The use of AI and ML has gained traction in oncology, particularly in the analysis of radiological images. Esteva et al. (2017) demonstrated that deep learning algorithms could accurately classify skin cancer images, surpassing the performance of dermatologists. Moreover, AI is also being used in the interpretation of genomic data to predict patient responses to specific therapies. Studies like Cortes et al. (2019) highlighted the potential of AI-based models to predict therapeutic outcomes based on complex patient data.

Despite the progress in precision oncology, challenges remain in implementing personalized treatments on a large scale. Issues such as data integration, patient access to genetic testing, and the high costs associated with genomic sequencing continue to hinder widespread adoption. Furthermore, the development of therapies targeting specific mutations is still in its early stages for many cancers. As highlighted by Collins et al. (2019), collaboration between researchers, clinicians, and patients is essential for overcoming these barriers and ensuring the success of personalized cancer treatments.

3. PROPOSED MODEL

The proposed model for advancing precision medicine in personalized cancer treatment integrates the following key components:

3.1 Genomic profiling and biomarker discovery

Comprehensive genomic profiling of tumors through NGS will identify somatic mutations, copy number variations, and gene expression patterns. The use of liquid biopsies, such as ctDNA and circulating tumor cells (CTCs), will provide a less invasive method for monitoring tumor dynamics in real-time.

3.2 Artificial intelligence and machine learning

AI algorithms will be employed to analyze complex datasets, including genetic information, clinical outcomes, and radiological images. By integrating data from various sources, the model will provide predictions on the effectiveness of specific therapies, enabling the customization of treatment plans for individual patients. **Deep learning** will be used to identify novel biomarkers and predict potential therapeutic targets that have not yet been explored.

3.3 Targeted therapy and immunotherapy

Based on the genomic and molecular data obtained, the model will recommend targeted therapies aimed at specific mutations (e.g., BRAF inhibitors for melanoma, ALK inhibitors for non-small cell lung cancer) and immunotherapies that activate the immune system to recognize and attack cancer cells. The inclusion of checkpoint inhibitors and CAR-T cell therapy will be considered, particularly in cancers with immune evasion mechanisms.

3.4 Real-time monitoring and adaptive treatment plans

The proposed model will leverage wearable devices and biomarkers to monitor patients' responses to treatment continuously. Adaptive treatment strategies will be employed, adjusting therapies based on real-time data to maximize efficacy and minimize adverse effects.

3.5 Interdisciplinary collaboration and patient-centric approach

Collaboration between clinicians, researchers, genetic counselors, and data scientists will be essential to successfully implement this model. Patients will be actively involved in decision-making, ensuring that treatments align with their preferences and values.

Treatment Plan Analysis Table 1 that can be used to evaluate personalized treatment strategies for cancer patients based on precision medicine, incorporating genetic profiling, biomarker discovery, targeted therapies, and AI-driven predictions:

4. TREATMENT PLAN DISCUSSION

Table 1: Treatment plan analysis based on precision medicine

Patient Group	Genomic Profile	Biomarkers Detected	Recommended Treatment Plan	Expected Outcome	Risk/Side Effects	Follow-Up Plan
Group 1: Non-Small Cell Lung Cancer (NSCLC)	EGFR Exon 19 deletion, ALK fusion gene	High expression of PD-L1, Tumor Mutational Burden (TMB)	Targeted therapy with **EGFR inhibitors (e.g., Erlotinib)**, **Immune checkpoint inhibitors (e.g., Pembrolizumab)**	Improved response rates, extended progression-free survival (PFS)	Risk of skin rash, diarrhea, fatigue, immune-related adverse events (irAEs)	Monitor PD-L1 expression and TMB levels, assess immune response via imaging and blood tests

Group 2: HER2-positive Breast Cancer	HER2 gene amplification	Low TMB, Moderate expression of estrogen receptor (ER)	**HER2-targeted therapies (e.g., Trastuzumab, Pertuzumab)**, **Chemotherapy (e.g., Docetaxel)**	Higher response rates, reduced relapse rates	Cardiotoxicity (heart failure), diarrhea, fatigue	Follow up with echocardiograms for heart function, regular CT/MRI for monitoring tumor size
Group 3: Melanoma (BRAF-mutant)	BRAF V600E mutation	Low expression of PD-L1, High TMB	**BRAF inhibitors (e.g., Vemurafenib)** combined with **MEK inhibitors (e.g., Cobimetinib)**, or **Immunotherapy (e.g., Nivolumab)**	Complete response in some patients, durable remission	Risk of cutaneous squamous cell carcinoma (SCC), fever, fatigue	Monitor for new skin lesions, follow-up imaging to assess response
Group 4: Colorectal Cancer (KRAS-mutant)	KRAS G12D mutation	High levels of ctDNA, High microsatellite instability (MSI)	**Chemotherapy (e.g., FOLFOX)**, **Immunotherapy (e.g., Nivolumab for MSI-high patients)**	Improved survival in MSI-high patients, limited benefit for non-MSI-high	Nausea, neutropenia, diarrhea, immune-related toxicity	Monitor ctDNA levels for early signs of recurrence, colonoscopy for metastasis
Group 5: Ovarian Cancer (BRCA1/2 mutation)	BRCA1/2 mutation	Elevated CA-125, Low expression of p53	**PARP inhibitors (e.g., Olaparib)**, **Platinum-based chemotherapy (e.g., Carboplatin)**	Prolonged progression-free survival (PFS), better overall survival	Risk of myelodysplastic syndrome, fatigue, anemia	Regular blood tests (CBC), CT/MRI scans for tumor assessment, monitor for secondary malignancies
Group 6: Acute Myeloid Leukemia (AML)	FLT3-ITD mutation, NPM1 mutation	High levels of CD33, High LDH	**Targeted therapy (e.g., Midostaurin for FLT3 mutations)**, **Chemotherapy (e.g., Cytarabine + Daunorubicin)**	Higher remission rates, improved overall survival (OS) for FLT3-positive patients	Risk of bleeding, neutropenia, nausea, infection	Regular bone marrow biopsy for remission assessment, CBC to monitor blood counts

- **Patient Group**: Specific cancer type or subtype based on genetic or molecular profiling (e.g., NSCLC, HER2-positive breast cancer).
- Genomic Profile: The specific genetic mutations or alterations identified in the patient's tumor (e.g., EGFR, HER2, BRAF mutations).
- Biomarkers Detected: Biomarkers that are identified either through liquid biopsy or tissue biopsy to guide treatment (e.g., PD-L1, TMB, ctDNA).
- Recommended Treatment Plan: The personalized treatment regimen based on the patient's genomic profile and detected biomarkers (e.g., targeted therapies, immunotherapy, chemotherapy).
- Expected Outcome: The anticipated response to the treatment plan, including survival rates, response rates, and the potential for remission.
- Risk/Side Effects: Common adverse effects or risks associated with the recommended treatments (e.g., cardiotoxicity, fatigue, immune-related adverse events).
- Follow-Up Plan: Monitoring strategies post-treatment, including tests (e.g., CT/MRI scans, blood work) and the evaluation of biomarkers (e.g., ctDNA, PD-L1) to assess the effectiveness and detect early signs of recurrence or

resistance.

4.1 Interpretation of the Table

This Treatment Plan Analysis Table 1 illustrates how precision medicine tailors cancer treatments based on individual genetic and molecular characteristics. By considering specific mutations and biomarkers, oncologists can recommend the most effective and targeted therapies, which are more likely to provide better clinical outcomes than traditional, one-size-fits-all approaches.

- Personalized approaches improve treatment efficacy while reducing side effects by targeting cancer cells more precisely.
- Regular monitoring of genetic markers like ctDNA, PD-L1, and TMB enables the early detection of treatment resistance or relapse, helping guide adaptive treatment plans.
- The table highlights the importance of multidisciplinary collaboration and continuous patient monitoring, which are critical for the successful implementation of precision medicine in cancer care.

This framework can be adapted to analyse and monitor cancer treatments for a wide variety of cancers, ensuring that each patient receives the most personalized, effective therapy based on their individual disease profile.



Figure 1: Treatment plan

Here is a stacked bar graph representing the treatment response rates by different treatment plans (e.g., HER2 inhibitors, BRAF inhibitors, and Immunotherapy). The categories represent the percentage of patients achieving Complete Response, Partial Response, Stable Disease, or Progressive Disease. Figure 1 explains about HER2 Inhibitors have a higher proportion of patients achieving Partial Response (50%), followed by Complete Response (20%). BRAF Inhibitors show a higher Complete Response (30%) and a similar pattern of Partial Response (40%). Immunotherapy has a strong Complete Response (40%), with fewer patients experiencing Progressive Disease (10%). This type of graph helps visualize the effectiveness of each treatment plan, comparing response rates across various cancer treatments.

5. CONCLUSION

The future of precision medicine in personalized cancer treatment holds immense promise, offering the potential for more effective, targeted, and individualized therapies. Advances in genomic sequencing, biomarker discovery, and AI-driven analytics are poised to revolutionize cancer care, allowing for better diagnosis, tailored treatments, and improved clinical outcomes. However, challenges such as cost, data complexity, and the need for interdisciplinary collaboration remain barriers to widespread adoption. Overcoming these challenges will require continued investment in research, technology, and healthcare infrastructure. The integration of precision medicine into routine oncology practice will ultimately transform the landscape of cancer treatment, offering patients more personalized and effective therapeutic options.

REFERENCES

[1] Mardis ER. Next-generation DNA sequencing methods. Annu. Rev. Genomics Hum. Genet.. 2008 Sep 22;9(1):387-402. https://doi.org/10.1146/annurev.genom.9.081307.164359

[2] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW. Cancer genome landscapes. science. 2013 Mar 29;339(6127):1546-58. https://doi.org/10.1126/science.1235122

[3] Diaz Jr LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature.

2012 Jun 28;486(7404):537-40. https://doi.org/10.1038/nature11219

[4] Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, Thrun S. Dermatologist-level classification of skin cancer with deep neural networks. nature. 2017 Feb;542(7639):115-8. https://doi.org/10.1038/nature21056

[5] Cortes JE, Santoro A. Artificial intelligence in oncology: Current and future applications. Cancer Journal. 2019;25(3):183-191.

[6] Collins FS, Varmus H. A new initiative on precision medicine. New England journal of medicine. 2015 Feb 26;372(9):793-5.

[7] Kavitha M. Environmental monitoring using IoT-based wireless sensor networks: A case study. Journal of Wireless Sensor Networks and IoT. 2024;1(1):32-36.

[8] Muralidharan J. Advancements in 5G technology: Challenges and opportunities in communication networks. Progress in Electronics and Communication Engineering. 2024;1(1):1-6.

[9] los Ríos-Escalante D, Contreras A, Jara P, Lara G, Latsague M, Rudolph E. A review knowledge of Chilean crayfishes (Decapoda: Parastacidae). International Journal of Aquatic Research and Environmental Studies. 2023 Nov 10;3(2):109-15. https://doi.org/10.70102/IJARES/V3I2/7

[10] Rajput A, Kumawat R, Sharma J, Srinivasulu A. Design of Novel High Speed Energy Efficient Robust 4: 2 Compressor. Journal of VLSI Circuits and Systems. 2024 Aug 27;6(2):53-64. https://orcid.org/0000-0003-2482-3637

[11] Muralidharan J. Innovative materials for sustainable construction: A review of current research. Innovative Reviews in Engineering and Science. 2024;1(1):16-20.

[12] Inayathullah N, Srilaxmi K, Vijayanand P. Comparitive study on culture economics of Litopenaus vannamei between summer and winter seasons along Tamilnadu coastal areas. International Journal of Aquatic Research and Environmental Studies. 2022 May 10;2(1):43-53. https://doi.org/10.70102/IJARES/V2I1/5

[13] Kabasa B, Chikuni E, Bates MP, Zengeni TG. Data Conversion: Realization of Code converter using Shift Register Modules. Journal of VLSI circuits and systems. 2023;5(01):8-19.

[14] Bita S, Balouch A, Mohammadian T. Determination of lethal concentration (LC50) of silver nanoparticles produced by biological and chemical methods in Asian seabass fish. International Journal of Aquatic Research and Environmental Studies. 2021 Nov 10;1(2):7-12. https://doi.org/10.70102/IJARES/V1I2/2

[15] Abbas MA, Hatem TM, Tolba MA, Atia M. Physical Design of Speed Improvised Factor in FPGA Applications. Journal of VLSI circuits and systems. 2023;5(01):61-6. https://doi.org/10.31838/jvcs/05.01.09